Abstract

 
 
 
 Purpose: To determine the effect of diosmetin on young, non-alcoholic fatty liver disease (NAFLD) rats.
 Methods: Five groups of SD rats were used: control group, high-fat diet group, low-dose diosmetin group, medium-dose diosmetin group, and high-dose diosmetin group, each with 10 rats. After 3 months, interleukin 6 (IL-6), IL-1β) and TNF-α) were assayed. Protein expressions of p-AMPKα, CPT-1 and PPAR-α, AMPKα, SREBP-1c and FAS were assayed.
 Results: In the high-fat diet group, the levels of p-AMPKα, CPT-1 and PPAR-α were lower than the corresponding control values, while p-AMPKα, CPT-1 and PPAR-α levels were dose-dependently higher in all diosmetin groups than in NAFLD group (p < 0.05). There were higher levels of SREBP-1c and FAS in the high-fat diet group than in control group, while SREBP-1c and FAS levels in all diosmetin groups were dose-dependently lower than the corresponding levels in NAFLD group. Serum IL-6, IL-1β and TNF-α levels in NAFLD group were raised, relative to control values (p < 0.05).
 Conclusion: Diosmetin alleviates NAFLD lesions induced by high-fat diet, slows down liver cell apoptosis, and inhibits inflammation via activation of AMPK pathway. Thus, diosmetin has potentials for use in the repair of hepatic damage induced by high-fat diet.
 
 
 
Highlights
It is known that NAFLD is a clinicopathological syndrome characterized by excessive fat deposition in liver cells due to alcohol and other liver-damaging factors, and it is an acquired acute liver injury [1]
Results from transferase-mediated dUTP nick labeling (TUNEL) staining showed that percentage cell apoptosis of rats in NAFLD group was increased, relative to control value, while percentage cell apoptosis values in the diosmetin groups were dose-dependently decreased, relative to the NAFLD group
These results suggest that diosmetin effectively reduces NAFLD lesions induced by high-fat diet and slows down liver cell apoptosis
Summary
It is known that NAFLD is a clinicopathological syndrome characterized by excessive fat deposition in liver cells due to alcohol and other liver-damaging factors, and it is an acquired acute liver injury [1]. With improvements in living standards and changes in diet and lifestyle in recent years, obesity and its related metabolic syndrome have become a global epidemic. It has been reported that NAFLD is a predisposing factor for chronic liver disease worldwide, with serious and adverse impact on human life and health [2]. It has been found that diosmetin exerts a variety of pharmacological effects such as anti-tumor, antioxidant, anti-inflammatory and antibacterial properties. Not much is known about the anti-NALFD effect of diosmetin [4]. The aim of this research was to study the anti-NAFLD
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
